More than 1 in 7 US adults-about 35.5 million people have chronic kidney disease (CKD), which increases the risk of many adverse events. α1-acid glycoprotein (AGP), has been associated with energy metabolism, which mitigates acute kidney injury (AKI) and its progression to CKD, and protect against renal fibrosis in animal studies. However, studies that used large population-based database research are limited. Therefore, this study aimed to investigate whether CKD prevalence is associated with serum α1-AGP levels in female adults in the US.
No takes yet. Share an insight, caveat, or question.
Sumin WU (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: